DYRK2 and triple-negative breast carcinoma: We have recently identified LDN192960 as a selective DYRK2 inhibitor and showed that LDN192960 could alleviate multiple myeloma and triple-negative breast cancer progression by inhibiting DYRK2-mediated proteasome phosphorylation (Banerjee et al., 2019).